

Cabotegravir for the prevention of HIV-1 in women: results of a randomised clinical trial

Lancet, The

399, 1779-1789

DOI: [10.1016/s0140-6736\(22\)00538-4](https://doi.org/10.1016/s0140-6736(22)00538-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long-acting injections for HIV prevention among women in sub-Saharan Africa. <i>Lancet, The</i> , 2022, , .	13.7	1
2	Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
3	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	2.0	6
4	Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California. <i>AIDS Patient Care and STDs</i> , 2022, 36, 254-262.	2.5	8
5	Estimating Benefits from Using On-Demand Oral Prep by MSM: A Comparative Modeling Study of the US and Thailand. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
6	How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 213-221.	3.8	8
7	Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 306-316.	1.9	5
8	Disrupting the status quo to achieve early inclusion of pregnant women in studies of new agents for prevention and treatment of HIV infection. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	0
9	Long-acting agents for HIV treatment and prevention. <i>Nature Medicine</i> , 2022, 28, 1542-1543.	30.7	3
10	Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa. <i>Aids</i> , 2022, 36, 1473-1475.	2.2	1
11	Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1898-1905.	1.0	7
12	New HIV prevention approaches: promise, praxis, and pitfalls. <i>Lancet, The</i> , 2022, 400, 257-259.	13.7	1
13	Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	13
14	Long-lasting HIV prevention drug could be game changer " but who will pay?. <i>Nature</i> , 2022, 608, 460-461.	27.8	1
15	Female Genital Fibroblasts Diminish the In Vitro Efficacy of PrEP against HIV. <i>Viruses</i> , 2022, 14, 1723.	3.3	0
17	Preexposure prophylaxis for HIV prevention. <i>Nurse Practitioner</i> , 2022, 47, 44-47.	0.3	0
18	Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?. <i>Current HIV/AIDS Reports</i> , 2022, 19, 384-393.	3.1	11
19	HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention. <i>PLoS Medicine</i> , 2022, 19, e1004102.	8.4	13

#	ARTICLE	IF	CITATIONS
20	Development of a Human Immunodeficiency Virus Risk Prediction Model Using Electronic Health Record Data From an Academic Health System in the Southern United States. <i>Clinical Infectious Diseases</i> , 2023, 76, 299-306.	5.8	7
22	In-depth knowledge to guide services for female sex workers. <i>Lancet HIV,the</i> , 2022, 9, e739-e740.	4.7	0
23	Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004097.	8.4	9
24	Impact of a clinical pharmacist within an HIV PrEP program for patients experiencing homelessness. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, 63, 324-329.	1.5	1
25	Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir. <i>Antiviral Research</i> , 2022, 208, 105427.	4.1	7
26	Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis. <i>Aids</i> , 2022, 36, 1897-1898.	2.2	4
27	Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis. <i>Drugs</i> , 2022, 82, 1489-1498.	10.9	2
28	A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. <i>Retrovirology</i> , 2022, 19, .	2.0	22
29	A Look at the Importance of Chirality in Drug Activity: Some Significant Examples. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10909.	2.5	21
30	Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1365-1380.	5.0	13
32	Monitoring antiretroviral therapy in low and middle-income countries: current status and future considerations. <i>Aids</i> , 2022, 36, 2071-2073.	2.2	0
33	Human Immunodeficiency Virus Treatment and Prevention for Pregnant and Postpartum Women in Global Settings. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 693-712.	1.9	1
34	New drug approvals for 2021: Synthesis and clinical applications. <i>European Journal of Medicinal Chemistry</i> , 2023, 245, 114898.	5.5	15
35	Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. <i>Lancet HIV,the</i> , 2022, 9, e857-e867.	4.7	16
36	How much could long-acting PrEP cost in South Africa?. <i>Lancet HIV,the</i> , 2022, 9, e814-e815.	4.7	0
37	HIV Prevention Utilizing Long-acting Injectables. , 2022, 1, 31.		0
38	Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa. , 2022, 1, 26.		0
39	Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation. <i>Clinical Infectious Diseases</i> , 2022, 75, S571-S578.	5.8	3

#	ARTICLE	IF	CITATIONS
40	Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs). <i>Clinical Infectious Diseases</i> , 2022, 75, S549-S556.	5.8	7
41	Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. <i>HIV Medicine</i> , 2023, 24, 568-579.	2.2	13
42	Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2022, 75, S541-S548.	5.8	5
43	Interrogating the promise of long-acting HIV pre-exposure prophylaxis. <i>Trends in Molecular Medicine</i> , 2022, , .	6.7	2
44	Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 1-11.	3.8	3
45	Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents. <i>Clinical Infectious Diseases</i> , 2022, 75, S562-S570.	5.8	6
46	Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. <i>EBioMedicine</i> , 2022, 86, 104361.	6.1	5
47	Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?. <i>HIV Medicine</i> , 2023, 24, 653-663.	2.2	5
48	Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2023, 41, 467-480.	3.3	2
49	Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 497-503.	3.0	3
50	Non- <i>Lactobacillus</i> -Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition. <i>Clinical Infectious Diseases</i> , 2023, 76, 1372-1381.	5.8	4
51	Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
52	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 63.	7.4	137
53	Optimizing the vaginal microbiome as a potential strategy to reduce heterosexual HIV transmission. <i>Journal of Internal Medicine</i> , 2023, 293, 433-444.	6.0	3
54	Long-acting PrEP: new opportunities with some drawbacks. <i>Lancet HIV</i> , 2023, 10, e213-e215.	4.7	0
55	Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2023, 10, e254-e265.	4.7	13
56	Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women. <i>Clinical Infectious Diseases</i> , 2023, 76, 1850-1853.	5.8	9
57	Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2023, 27, 102733.	0.6	3

#	ARTICLE	IF	CITATIONS
58	Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. <i>Aids</i> , 2023, 37, 957-966.	2.2	6
59	Investigational drugs for HIV: trends, opportunities and key players. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 127-139.	4.1	1
60	New designs for HIV-1 integrase inhibitors: a patent review (2018-present). <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 51-66.	5.0	2
61	Medical Complications of Injection Drug Use – Part II. , 2023, 2, .		1
62	The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission. <i>Current HIV/AIDS Reports</i> , 0, , .	3.1	0
63	Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 228, 115307.	2.8	3
64	Development and validation of a multiplexed assay for the measurement of long-acting hormonal contraceptives in plasma via liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 228, 115321.	2.8	0
65	Personalizing prevention: Advances in pharmacotherapy for <sc>HIV</sc> prevention. <i>Pharmacotherapy</i> , 2023, 43, 305-320.	2.6	1
66	An update on expanding HIV preexposure prophylaxis. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2023, 36, 17-24.	0.3	1
67	Addressing the evidence gap for HIV prevention in pregnancy. <i>Lancet HIV</i> , the, 2023, 10, e144-e145.	4.7	0
68	High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. <i>Journal of Community Health</i> , 2023, 48, 513-521.	3.8	4
69	High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study. <i>PLoS Medicine</i> , 2023, 20, e1004088.	8.4	3
70	Preferences for PrEP modalities among gay, bisexual, and other men who have sex with men from Brazil, Mexico, and Peru: a cross-sectional study. <i>Therapeutic Advances in Infectious Disease</i> , 2023, 10, 204993612311535.	1.8	3
71	Preventing HIV and achieving pregnancy among HIV sero-different couples: Pilot study of a safer conception intervention in Zimbabwe. <i>PLOS Global Public Health</i> , 2023, 3, e0000796.	1.6	0
72	Dynamics of Human Immunodeficiency Virus Type 1 A6 Variant Transmissions Between Poland and Ukraine. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0
73	Study protocol for an efficacy trial of the ‘‘PrEP for Health’’ intervention to increase HIV PrEP use among people who inject drugs. <i>BMC Public Health</i> , 2023, 23, .	2.9	3
75	Conference proceedings from hybrid 25th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 0, , .	1.8	0
76	Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	3.2	2

#	ARTICLE	IF	CITATIONS
77	Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are. <i>Journal of General Internal Medicine</i> , 2023, 38, 2816-2818.	2.6	2
78	Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e44961.	2.6	2
81	<scp>PrEP</scp> for women in Europe: a systematic literature review. <i>HIV Medicine</i> , 2023, 24, 765-776.	2.2	1
82	Infectious Diseases: What You May Have Missed in 2022. <i>Annals of Internal Medicine</i> , 2023, 176, 701-717.	3.9	3
83	Optimizing the pipeline of multipurpose prevention technologies: opportunities across women's reproductive lifespans. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	4
84	Protocol for WeExPAnd: a prospective, mixed-methods pilot demonstration study to increase access to pre-exposure prophylaxis among women vulnerable to HIV infection in the Southern USA. <i>BMJ Open</i> , 2023, 13, e075250.	1.9	0
85	Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis. <i>Southern African Journal of HIV Medicine</i> , 2023, 24, .	0.9	0
86	Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis. <i>JMIR Public Health and Surveillance</i> , 0, 9, e46767.	2.6	0
87	Prevention, treatment and cure of HIV infection. <i>Nature Reviews Microbiology</i> , 2023, 21, 657-670.	28.6	21
88	The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. <i>Lancet HIV</i> ,the, 2023, 10, e404-e411.	4.7	11
89	Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women. <i>AIDS and Behavior</i> , 2023, 27, 3596-3602.	2.7	0
90	Stand-alone model for delivery of oral HIV pre-exposure prophylaxis in Kenya: a single-arm, prospective pilot evaluation. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
91	Implementation of HIV prevention strategies globally. <i>Lancet HIV</i> ,the, 2023, , .	4.7	0
92	Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
93	Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. <i>Aids</i> , 0, , .	2.2	2
94	From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications. <i>Pathogens</i> , 2023, 12, 924.	2.8	0
95	What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	2
96	Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3

#	ARTICLE	IF	CITATIONS
97	Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
98	Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	2
99	Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC). <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	1
100	Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub-Saharan Africa community stakeholders. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	1
101	Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. <i>Advanced Drug Delivery Reviews</i> , 2023, 200, 115009.	13.7	4
102	Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	8
103	Global HIV control: is the glass half empty or half full?. <i>Lancet HIV</i> , 2023, 10, e617-e622.	4.7	4
104	Developing HIV risk prediction tools in four African settings. <i>Tropical Medicine and International Health</i> , 2023, 28, 720-730.	2.3	0
105	HIV pre-exposure prophylaxis and incidence of sexually transmitted infections in Brazil, 2018 to 2022: An ecological study of PrEP administration, syphilis, and socioeconomic indicators. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011548.	3.0	1
106	Is Higher Adherence Required for Women using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Preexposure Prophylaxis?. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0
107	HIV infection. <i>Nature Reviews Disease Primers</i> , 2023, 9, .	30.5	15
108	Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV. <i>EBioMedicine</i> , 2023, 95, 104764.	6.1	0
109	<i>Pandemien.</i> , 2023, , 123-136.		0
110	Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology. <i>PLoS ONE</i> , 2023, 18, e0290568.	2.5	1
111	Chronic Hepatitis B Infection: New Approaches towards Cure. <i>Biomolecules</i> , 2023, 13, 1208.	4.0	2
112	Significant Publications on Infectious Diseases Pharmacotherapy in 2022. <i>Journal of Pharmacy Practice</i> , 0, , .	1.0	0
113	Safety surveillance for PrEP in pregnant and breastfeeding women. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	1
114	Preexposure Prophylaxis for the Prevention of HIV. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 746.	7.4	6

#	ARTICLE	IF	CITATIONS
115	HIV Pre-Exposure Prophylaxis, Blood Donor Deferral, Occult Infection, and Risk of HIV Transmission by Transfusion: A Fine Balance Between Evidence-Based Donor Selection Criteria and Transfusion Safety. <i>Transfusion Medicine Reviews</i> , 2023, 37, 150754.	2.0	0
116	Updated USPSTF Recommendations for Preexposure Prophylaxis—New Choices, New Obstacles. <i>JAMA Internal Medicine</i> , 2023, 183, 1054.	5.1	0
117	Preexposure Prophylaxis to Prevent Acquisition of HIV. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 736.	7.4	8
118	Program impact and potential pitfalls of multi-purpose technologies (MPTs) for HIV prevention and contraception. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
119	Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	0
120	Side effects of antiviral drugs. <i>Side Effects of Drugs Annual</i> , 2023, , .	0.6	0
121	Control groups for HIV prevention efficacy trials: what does the future hold?. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 349-356.	3.8	2
122	Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. <i>The Lancet Global Health</i> , 2023, 11, e1648-e1657.	6.3	1
123	Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
124	Optimising oral PrEP while awaiting long-acting cabotegravir. <i>Lancet HIV</i> , the, 2023, , .	4.7	0
125	Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. <i>Nature Medicine</i> , 2023, 29, 2748-2752.	30.7	3
126	Integrase inhibitors: current protagonists in antiretroviral therapy. <i>Immunotherapy</i> , 2023, 15, 1477-1495.	2.0	0
127	Updates in the Approach to Pediatric HIV Care and Prevention. <i>Current Treatment Options in Pediatrics</i> , 0, , .	0.6	0
128	Measuring the performance of HIV self-testing at private pharmacies in Kenya: a cross-sectional study. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	2
129	Dynamic choice HIV prevention intervention at outpatient departments in rural Kenya and Uganda: a randomized trial. <i>Aids</i> , 0, , .	2.2	0
130	Current drugs for HIV-1: from challenges to potential in HIV/AIDS. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
131	Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe. <i>Lancet Regional Health - Europe</i> , The, 2023, 34, 100738.	5.6	5
132	A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine. <i>International Journal of Translational Medicine</i> , 2023, 3, 461-478.	0.4	0

#	ARTICLE	IF	CITATIONS
133	Young People Need More HIV Prevention Options, Delivered in an Acceptable Way. <i>Journal of Adolescent Health</i> , 2023, 73, S8-S10.	2.5	2
134	Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women. <i>Nature Medicine</i> , 2023, 29, 2753-2762.	30.7	4
135	Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01. <i>Nature Communications</i> , 2023, 14, .	12.8	0
136	Long-acting cabotegravir PrEP: a time for cautious optimism. <i>Lancet HIV,the</i> , 2023, 10, e756-e757.	4.7	0
137	Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. <i>Lancet HIV,the</i> , 2023, 10, e767-e778.	4.7	1
138	Overcoming structural barriers to diffusion of HIV pre-exposure prophylaxis. , 2023, 7, .		0
139	Prevalence of Curable Sexually Transmitted Infections in a Population-Representative Sample of Young Adults in a High HIV Incidence Area in South Africa. <i>Sexually Transmitted Diseases</i> , 2023, 50, 796-803.	1.7	0
140	Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
141	Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa. <i>AIDS and Behavior</i> , 2024, 28, 936-950.	2.7	0
143	The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. <i>Aids</i> , 2024, 38, 589-594.	2.2	0
144	Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01). <i>Journal of Infectious Diseases</i> , 0, , .	4.0	0
145	Planning for PrEP: are national surveillance data sufficient?. <i>Lancet HIV,the</i> , 2023, 10, e759-e760.	4.7	0
146	HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic. <i>Drugs</i> , 0, , .	10.9	0
147	Availability of Testing for Sexually Transmitted Infections and HIV in U.S. Outpatient Mental Healthcare Settings. <i>AIDS and Behavior</i> , 2024, 28, 1029-1038.	2.7	0
149	An update on long-acting agents in HIV therapy. <i>Future Virology</i> , 2023, 18, 881-893.	1.8	0
150	HIV epidemiology, prevention, treatment, and implementation strategies for public health. <i>Lancet, The</i> , 2024, 403, 471-492.	13.7	0
151	Adolescents and young adults are the most undiagnosed of HIV and virally unsuppressed in Eastern and Southern Africa: Pooled analyses from five population-based surveys. <i>PLOS Global Public Health</i> , 2023, 3, e0002398.	1.6	0
152	Advancements in Cell-Based Therapies for HIV Cure. <i>Cells</i> , 2024, 13, 64.	4.1	0

#	ARTICLE	IF	CITATIONS
153	Study design approaches for future active-controlled HIV prevention trials. <i>Statistical Communications in Infectious Diseases</i> , 2023, 15, .	0.2	0
154	Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. <i>Pharmaceutics</i> , 2024, 16, 183.	4.5	0
156	Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. <i>Pharmacoeconomics</i> , 2024, 42, 447-461.	3.3	0
157	Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1615.	4.1	0
158	Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP. <i>Pharmaceutics</i> , 2024, 16, 201.	4.5	0
159	Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border Metroplex. <i>AIDS and Behavior</i> , 2024, 28, 1650-1661.	2.7	0
161	Intention to Use Different Formulations of Longer Acting HIV Pre-Exposure Prophylaxis Among Transgender and Gender Expansive Individuals: The Roles of Social Vulnerability and Medical Mistrust. <i>AIDS Patient Care and STDs</i> , 2024, 38, 51-60.	2.5	0
162	My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya. <i>Journal of the International AIDS Society</i> , 2024, 27, .	3.0	0
163	Knowledge of HIV transmission, prevention strategies and U=U among adult sexual and gender minorities in Brazil. <i>Journal of the International AIDS Society</i> , 2024, 27, .	3.0	0
164	Centring the health of women across the HIV research continuum. <i>Lancet HIV</i> , 2024, 11, e186-e194.	4.7	0
165	Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 912.	7.4	0
166	HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 930.	7.4	0
167	Perceptions of and preferences for PrEP use among African American women and providers in the U.S. South: a qualitative study. <i>Psychology and Health</i> , 0, , 1-20.	2.2	0
168	What does the scale of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?. <i>Journal of the International AIDS Society</i> , 2024, 27, .	3.0	0
169	Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2024, 95, 447-455.	2.1	0
170	The Impact of Human Immunodeficiency Virus on Women in the United States. <i>Nursing Clinics of North America</i> , 2024, 59, 165-181.	1.5	0
171	Incidence of sexually transmitted infections and screening models among pre-exposure prophylaxis users. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2024, , .	0.3	0
172	Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. <i>Clinical Pharmacology and Therapeutics</i> , 0, , .	4.7	0

#	ARTICLE	IF	CITATIONS
173	Co-designing strategies to implement long-acting injectable PrEP for sexual minority men in Chicago: a study protocol for an innovation tournament and implementation mapping. <i>Implementation Science Communications</i> , 2024, 5, .	2.2	0
174	Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030. <i>Lancet, The</i> , 2024, 403, 1313-1315.	13.7	0
175	Leveling Up PrEP: Implementation Strategies at System and Structural Levels to Expand PrEP Use in the United States. <i>Current HIV/AIDS Reports</i> , 2024, 21, 52-61.	3.1	0
176	Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential. <i>Expert Review of Anti-Infective Therapy</i> , 2024, 22, 153-167.	4.4	0
177	Identifying Implementation Strategies to Enhance HIV Pre-Exposure Prophylaxis Uptake Among Black Cisgender Women in New Orleans, Louisiana. <i>AIDS Patient Care and STDs</i> , 2024, 38, 144-150.	2.5	0